Pulmonary arterial hypertension in human immunodeficiency virus infections
Pulmonary arterial hypertension (PAH) is an important health issue in the twenty-first century. The introduction of highly active retroviral therapy has prolonged survival in patients infected with the human immunodeficiency virus (HIV), and this has led to the emergence of new health issues, including PAH, in those patients. This review considers the advances in understanding the pathophysiology of PAH in HIV infections and the approaches to the treatment of these patients. Keywords: Pulmonary arterial hypertension, HIV, pathophysiology, treatment
Authors
- Myrian Vinan-Vega (ORCID: https://orcid.org/0000-0002-0357-4419)
- Arunee Motes (ORCID: https://orcid.org/0000-0002-9557-9507)
- KENNETH M. NUGENT (ORCID: https://orcid.org/0000-0003-2781-4816)
- Tushi Singh
Institutions
- Texas Tech University (US)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- The Southwest Respiratory and Critical Care Chronicles
- Published
- 2024-10-25
- DOI
- https://doi.org/10.12746/swrccc.v12i53.1395
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00